Biosimilar user fee reauthorization negotiators couldn’t avoid disagreement during their first session, as two industry factions emerged over regulatory science issues.
Representatives of the Biosimilars Forum and the Association for Accessible Medicines and its Biosimilars Council, which advocate for biosimilars and...